Cambridge, UK, 18th November 2020 – TRx Biosciences is pleased to announce the opening of its new R&D facility within the Accelerator Unit at the Babraham Research Campus. The TRx team will immediately commence development and optimisation of TRx’s novel oral drug delivery platform, offering a step-change in drug biodistribution.

TRx CEO, Dr Robin Bannister said “I have fond memories throughout my career of this site and am proud to base TRx Biosciences at Babraham from the outset. The company cannot help to benefit from the first class facilities and proximity to biopharma companies shaping the future of disease treatment.